Trial Profile

Targeted Treatment Early With Etanercept Plus Methotrexate Versus T2T Care for DMARD-naive Early RA Patients. A Prospective, Longitudinal Cohort Study With Embedded Pilot Randomised Controlled Trial to Assess Treatment Rationalisation Based on naive T-cell Stratification

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etanercept (Primary) ; Methotrexate (Primary) ; Hydroxychloroquine; Sulfasalazine
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms TEEMS

03 Jul 2024 According to ISRCTN: Current Controlled Trials The trial is Expected to end on 8 Apr 2024
03 Jul 2024 Status changed from not yet recruiting to active, no longer recruiting.
29 Jan 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com